HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


BMY: Bristol Myers Squibb Co - Stock News Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Company News |  Zacks Commentary
BRISTOL MYERS SQUIBB CO (NYSE)
BMY 24.46 0.43 (1.79%) Vol.  24,664,695 16.00 CST

Nov 20, 2009 U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)
Nov 20, 2009 Bristol-Myers Squibb Looking Higher
Nov 20, 2009 Bristol Meyers Squibb Looking Higher
Nov 20, 2009 Critical Alerts for Chevron, Bristol-Myers Squibb, Gold Fields, Novellus, and Host Hotels Released by Seven Summits Research
Nov 17, 2009 Moody's says Bristol Myers ratings, outlook unchanged by planned separation of Mead Johnson Nutrition
Nov 17, 2009 Bristol-Myers Squibb to spin off Mead Johnson
Nov 17, 2009 Bristol-Myers announces split-off of Mead Johnson Nutrition Company
Nov 17, 2009 Apollo Global Announces Executive Appointments
Nov 17, 2009 Trading Overview for Poniard Pharmaceuticals Inc. Issued by Beacon Equity
Nov 17, 2009 Chartpoppers: Bristol Myers to Divest Nutritional Division, reported by chartpoppers.com
Nov 16, 2009 Bristol-Myers Squibb (BMY) Bullish Technical Alert - Trend Up 12.2%
Nov 16, 2009 Fitch: Bristol-Myers Squibb's Ratings Unlikely to be Affected by Mead Johnson Spin-off
Nov 16, 2009 Bristol-Myers Squibb To Split Off Holdings In Mead Johnson (BMY)
Nov 15, 2009 Bristol-Myers Squibb Announces Split-Off of Mead Johnson
Nov 15, 2009 Mead Johnson to File Registration Statement; Comments on Bristol-Myers Squibb Announcement to Split-off Mead Johnson
 
ZACKS COMMENTARY FOR BMY
Nov 20, 2009 Zacks Blog: Pozen Initiates New Phase III
Nov 20, 2009 Zacks Blog: AstraZeneca Seeks FDA Approval
Nov 16, 2009 Zacks Blog: Bristol Divests Nutritional Segment
Nov 16, 2009 Zacks Blog: Company News for November 16, 2009
Nov 13, 2009 Zacks Blog: Another Win for Mylan
Nov 12, 2009 Zacks Blog: Glaxo Reports Higher Revenues
Nov 09, 2009 Zacks Blog: Big Pharma and Biotech
Nov 02, 2009 Zacks Blog: Gilead’s Positive Data
Nov 02, 2009 Zacks Equity Research: Report for BMY
Oct 23, 2009 Zacks Blog: Isis Diabetes Drug Shows Promise
Oct 22, 2009 Zacks Blog: Bristol-Myers Beats by a Penny
Oct 22, 2009 Zacks Blog: Stock Market News for October 22, 2009

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research